No profile data available.
Omeros Corporation (OMER) is a healthcare company in the organ transfer treatment drugs industry, based in Seattle, United States, with about 175 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$3.35 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $28.53 million. Its market capitalization was $1.44 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Omeros reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $28.53 million.
$1.44 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (organ transfer treatment drugs) include Mesoblast Limited (MESO), Syndax Pharmaceuticals, Inc. (SNDX), Eledon Pharmaceuticals, Inc. (ELDN), Equillium, Inc. (EQ).